R. Douglas Hulse

Executive Director, The Sage Group

Mr. Hulse has over forty years experience building new businesses based on new technology, either in a deal-making or operating role, most recently in the area of biopharmaceuticals.

For nearly sixteen years he has served as an Executive Director and Principal at The Sage Group, a strategic transactions consultancy.  He has led M&A, corporate partnering, valuation and strategic assignments in the biotechnology, pharmaceutical and medical device industries.  Areas of particular concentration include oncology, wound healing, blood substitutes and drug delivery technologies.

While an Executive Director of The Sage Group, he served as President and Chief Operating Officer of Hemispherx Biopharma, a public biotechnology company in Philadelphia developing novel double stranded RNA therapeutics for antiviral and vaccine applications.

Before joining the Sage Group, he built the business development activity at Enzon, Inc., an emerging biopharmaceutical company exploiting proprietary drug delivery technologies and a leading company in protein replacement therapies, as a consultant and later as Vice President of Business Development, Mr. Hulse completed over 30 deals in his last three years at Enzon.

Prior to joining Enzon, Mr. Hulse specialized in high technology start-ups, serving as Founder and Chief Executive Officer for growth companies such as i-STAT Corporation (chemical microsensors), Sunstone, Inc. (Optronics), Envirometrics (fiber optic sensors), SDTX Technologies (hazardous materials remediation) and Polycyclose Technologies (cyclodextrin derivatives).

Previously, he has been a Vice President of Engelhard Industries, a leading precious metals technology company, responsible for new ventures, diversification, and strategic planning, and a Vice President and General Manager with Halcon International, where he managed a $20 million petrochemical catalyst division, with full P&L responsibility.

As Director of Business Planning at Halcon, Mr. Hulse led the team establishing the largest chemical joint venture in Japan as well as acted as principal business negotiator in borrowing over $250 million in a project financing for a major chemical complex in Texas.

He is a Phi Beta Kappa graduate of Princeton University in Chemistry and holds Masters Degrees in Chemical Engineering and Industrial Management from MIT.

Mr. Hulse is a member of the Licensing Executives Society and a Certified Licensing Professional.  He serves on the Advisory Board of the Commercialization Center for Innovative Technology (CCIT) in New Brunswick, New Jersey as well as on the Boards of SDTX Technologies, Inc., Captiva Technologies, Inc., and Carnegie Venture Resources, Inc.